{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:08:06Z","timestamp":1792728486497,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.17128","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T15:01:06Z","timestamp":1626361266000},"page":"e2117128","source":"Crossref","is-referenced-by-count":155,"title":["High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder"],"prefix":"10.1001","volume":"4","author":[{"given":"Andrew A.","family":"Herring","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Highland Hospital\u2014Alameda Health System, Oakland, California"},{"name":"Department of Emergency Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan A.","family":"Vosooghi","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Highland Hospital\u2014Alameda Health System, Oakland, California"},{"name":"Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Luftig","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Highland Hospital\u2014Alameda Health System, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Highland Hospital\u2014Alameda Health System, Oakland, California"},{"name":"Department of Emergency Medicine, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Yale Center for Analytical Sciences, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Dziura","sequence":"additional","affiliation":[{"name":"Yale Center for Analytical Sciences, Yale University, New Haven, Connecticut"},{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn F.","family":"Hawk","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"McCormack","sequence":"additional","affiliation":[{"name":"Ronald O. Perelman Department of Emergency Medicine, NYU Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Saxon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"D\u2019Onofrio","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Chronic Disease Epidemiology Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"issue":"6","key":"zoi210515r3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.annemergmed.2018.01.052","article-title":"Opportunities for prevention and intervention of opioid overdose in the emergency department.","volume":"71","author":"Houry","year":"2018","journal-title":"Ann Emerg Med"},{"issue":"26","key":"zoi210515r4","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMp1811988","article-title":"Emergency departments: a 24\/7\/365 option for combating the opioid crisis.","volume":"379","author":"D\u2019Onofrio","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi210515r6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s13181-019-00712-3","article-title":"ACMT position statement: buprenorphine administration in the emergency department.","volume":"15","author":"Wax","year":"2019","journal-title":"J Med Toxicol"},{"key":"zoi210515r7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.drugpo.2019.06.019","article-title":"\u201cThey\u2019re making it so hard for people to get help:\u201d motivations for non-prescribed buprenorphine use in a time of treatment expansion.","volume":"71","author":"McLean","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"3","key":"zoi210515r8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009-2018.","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"zoi210515r9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/pds.v29.6","article-title":"Rise and regional disparities in buprenorphine utilization in the United States.","volume":"29","author":"Pashmineh Azar","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"20","key":"zoi210515r10","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.3390\/ijerph17207535","article-title":"Misalignment of stakeholder incentives in the opioid crisis.","volume":"17","author":"Boloori","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"zoi210515r11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4561","article-title":"Barriers and facilitators to clinician readiness to provide emergency department-initiated buprenorphine.","volume":"3","author":"Hawk","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi210515r15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dar.v39.2","article-title":"High-dose buprenorphine for treatment of high potency opioid use disorder.","volume":"39","author":"Danilewitz","year":"2020","journal-title":"Drug Alcohol Rev"},{"issue":"4","key":"zoi210515r16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/02791072.2006.10400589","article-title":"Single dose of 24 milligrams of buprenorphine for heroin detoxification: an open-label study of five inpatients.","volume":"38","author":"Ang-Lee","year":"2006","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"zoi210515r17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.annemergmed.2018.11.032","article-title":"Managing opioid withdrawal in the emergency department with buprenorphine.","volume":"73","author":"Herring","year":"2019","journal-title":"Ann Emerg Med"},{"issue":"2","key":"zoi210515r18","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic.","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi210515r19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0376-8716(00)00141-1","article-title":"Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans.","volume":"61","author":"Amass","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"zoi210515r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"zoi210515r21","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on \u00b5-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"zoi210515r22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annemergmed.2019.07.030","article-title":"Characteristics and receipt of medication treatment among young adults who experience a nonfatal opioid-related overdose.","volume":"75","author":"Bagley","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"3","key":"zoi210515r23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.annemergmed.2014.03.025","article-title":"Looking through the retrospectoscope: reducing bias in emergency medicine chart review studies.","volume":"64","author":"Kaji","year":"2014","journal-title":"Ann Emerg Med"},{"issue":"1","key":"zoi210515r24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature.","volume":"151","author":"Kempen","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"zoi210515r25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses.","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"zoi210515r27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS).","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"zoi210515r28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1176\/rcp2.v1.1","article-title":"Shared decision-making tool for treatment of perinatal opioid use disorder.","volume":"1","author":"Guille","year":"2019","journal-title":"Psychiatr Res Clin Pract"},{"issue":"13","key":"zoi210515r29","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jama.2017.0616","article-title":"Prime time for shared decision making.","volume":"317","author":"Spatz","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"zoi210515r30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"4","key":"zoi210515r32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1037\/1064-1297.3.4.424","article-title":"Measurement of drug craving during naloxone-precipitated withdrawal in methadone-maintained volunteers.","volume":"3","author":"Schuster","year":"1995","journal-title":"Exp Clin Psychopharmacol"},{"issue":"16","key":"zoi210515r33","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial.","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"issue":"2-3","key":"zoi210515r34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.drugalcdep.2007.04.006","article-title":"Sublingual buprenorphine\/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.","volume":"90","author":"Rosado","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi210515r35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1213\/ANE.0b013e31821ae3f7","article-title":"Performance characteristics and validation of the Opioid-Related Symptom Distress Scale for evaluation of analgesic side effects after orthopedic surgery.","volume":"113","author":"Yadeau","year":"2011","journal-title":"Anesth Analg"},{"issue":"5","key":"zoi210515r36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4996","article-title":"Overcoming barriers to prescribing buprenorphine in the emergency department.","volume":"3","author":"Kim","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi210515r37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsat.2019.08.002","article-title":"Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: results from a multisite randomized trial of adults with opioid use disorder.","volume":"106","author":"Evans","year":"2019","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"zoi210515r38","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/ajad.v24.7","article-title":"Treatment outcomes in opioid dependent patients with different buprenorphine\/naloxone induction dosing patterns and trajectories.","volume":"24","author":"Jacobs","year":"2015","journal-title":"Am J Addict"},{"key":"zoi210515r39","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108673","article-title":"Voting with their feet: social factors linked with treatment for opioid use disorder using same-day buprenorphine delivered in California hospitals.","volume":"222","author":"Kalmin","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi210515r40","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102696","article-title":"Trajectories of retention in opioid agonist therapy in a Canadian setting.","volume":"77","author":"Soc\u00edas","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"2","key":"zoi210515r41","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/0310057X1704500217","article-title":"Buprenorphine-related complications in elderly hospitalised patients: a case series.","volume":"45","author":"Richards","year":"2017","journal-title":"Anaesth Intensive Care"},{"issue":"4","key":"zoi210515r42","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/15563650.2020.1814318","article-title":"Respiratory depression following medications for opioid use disorder (MOUD)-approved buprenorphine product oral exposures: National Poison Database System 2003-2019.","volume":"59","author":"Darracq","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"zoi210515r43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13722-017-0072-2","article-title":"Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.","volume":"12","author":"Bhatraju","year":"2017","journal-title":"Addict Sci Clin Pract"},{"key":"zoi210515r44","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108314","article-title":"Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance.","volume":"216","author":"Shover","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi210515r45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","article-title":"Fentanyl in the US heroin supply: a rapidly changing risk environment.","volume":"46","author":"Ciccarone","year":"2017","journal-title":"Int J Drug Policy"},{"key":"zoi210515r46","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.549272","article-title":"Reconsidering the usefulness of adding naloxone to buprenorphine.","volume":"11","author":"Blazes","year":"2020","journal-title":"Front Psychiatry"},{"key":"zoi210515r5","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Medicine, Science, and Engineering","year":"2019"},{"key":"zoi210515r1","unstructured":"Ahrnsbrak? R, Bose? J, Hedden? SL, Lipari? RN, Park-Lee? E; Substance Abuse and Mental Health Administration. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health (HHS publication No. SMA 17-5044, NSDUH series H-52). Published September 2017. Accessed June 7, 2021. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-FFR1-2016\/NSDUH-FFR1-2016.htm"},{"key":"zoi210515r2","unstructured":"National Institute on Drug Abuse. Opioid overdose crisis. Published 2020. Updated March 11, 2021. Accessed June 1, 2020. https:\/\/www.drugabuse.gov\/drugs-topics\/opioids\/opioid-overdose-crisis"},{"key":"zoi210515r12","unstructured":"Substance Abuse and Mental Health Administration. TIP 63: medications for opioid use disorder. Published May 2020. Accessed June 8, 2021. https:\/\/store.samhsa.gov\/product\/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document\/PEP20-02-01-006"},{"key":"zoi210515r13","unstructured":"Providers Clinical Support System. Waiver training for physicians. Accessed April 8, 2021. https:\/\/pcssnow.org\/medications-for-opioid-use-disorder\/waiver-training-for-physicians\/"},{"key":"zoi210515r14","unstructured":"US Food and Drug Administration. Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) prescribing information. Published 2002. Updated February 2018. Accessed June 8, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020732s018lbl.pdf"},{"key":"zoi210515r26","unstructured":"California Department of Health Care Services. The California Bridge Program. Accessed June 8, 2021. https:\/\/cabridge.org\/"},{"key":"zoi210515r31","unstructured":"National Cancer Institute; National Institutes of Health; US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0: NIH publication 09-7473. Published November 27, 2017. Accessed September 12, 2019. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2781956\/herring_2021_oi_210515_1625699918.90746.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T15:01:21Z","timestamp":1626361281000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2781956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.17128","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]}}}